Johnson & Johnson is expecting its newly-approved Imaavy to be a multibillion-dollar blockbuster across several conditions. But a stumble in a major disease category could hurt those plans.
Imaavy (nipocalimab) failed a Phase 2a rheumatoid ...
↧